Aislinn Antrim, Managing Editor

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.

A panel of experts at the Asembia 2022 Specialty Pharmacy Summit discussed some of the obstacles in providing medications approved under Emergency Use Authorization.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

Women in the study had higher rates of urgent procedures and were in poorer health when they received surgery.

Evusheld concentrations remained elevated in serum for 6 months after administration, supporting that a single dose could provide long-term protection against COVID-19.

Up to 50% of all patients with breast cancer have tumors with a HER2 immunohistochemistry level not currently eligible for HER2-targeted therapy.

Oncologists and rheumatologists reported the highest costs to their practices at $6700 and $7900 per month, respectively.

With Epsolay treatment, inflammatory lesions of rosacea were reduced by nearly 70% by the end of both 12-week trials compared with a 38% to 46% reduction with the vehicle cream.

Of the 53 pediatric patients enrolled in the CARAVAN study, no new safety signals were apparent for patients treated with remdesivir.

Patients taking the product should consult with their physician or pharmacist to determine whether they have the affected product.

The first cases were identified in October 2021 at a children’s hospital in Alabama that admitted 5 children with significant liver injury, including some with acute liver failure.

The booster vaccine candidate includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants such as the Omicron variant.

Among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities in the management of the chronic condition.

Asthma contributed most to the risk of high blood pressure and coronary heart disease.

When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures significantly decline.

Medicaid expansion implementation was associated with a decrease in the number of uninsured patients from 6.7% pre-expansion to 3.6% post-expansion.

Heart-related complications in children with COVID-19 are uncommon, but case reports have noted cardiogenic shock, myocarditis, pericarditis, and arrhythmias.

The companies plan to submit these data to the FDA in the coming days for an Emergency Use Authorization of a booster dose for children ages 5 through 11 in the United States.

Vusolimogene oderparepvec is in development for the treatment of multiple skin cancers either alone or in combination with anti-PD1 therapy.

The FDA previously granted Fast Track Designation for the combination of lifileucel and pembrolizumab in metastatic melanoma.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Numbers have remained below prepandemic levels.

Those hospitalized for COVID-19 were 21% more likely to develop shingles.

If all HHC agencies adopted policies requiring staff influenza vaccinations, the researchers predicted an 11.25% reduction in the rate of hospital transfers due to respiratory infections.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.